Morgan Stanley Initiates Coverage On Mural Oncology with Overweight Rating, Announces Price Target of $13
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Judah Frommer has initiated coverage on Mural Oncology (NASDAQ:MURA) with an Overweight rating and set a price target of $13.

April 04, 2024 | 10:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley initiated coverage on Mural Oncology with an Overweight rating and a price target of $13.
The initiation of coverage by a major financial institution like Morgan Stanley, especially with an Overweight rating, typically signals confidence in the company's future performance. The set price target of $13 suggests a positive outlook on the stock's value, potentially influencing investor sentiment and driving short-term price movement upwards.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100